Interleukin-1 receptor antagonist - Pharmacia

Drug Profile

Interleukin-1 receptor antagonist - Pharmacia

Alternative Names: Interleukin-1 receptor antagonist protein; IRAP; Recombinant human interleukin-1 receptor antagonist protein; Recombinant interleukin-1 receptor antagonist protein; rIRAP

Latest Information Update: 28 Feb 1996

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Inflammation; Rheumatic disorders; Type 1 diabetes mellitus

Most Recent Events

  • 28 Feb 1996 A new preclinical study has been added to the Diabetes pharmacodynamics section .
  • 28 Feb 1996 The new ATC/EphMRA codes for interleukin-1 receptor antagonist are A10X/A10X.
  • 28 Feb 1996 No-Development-Reported for Type-1 diabetes mellitus in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top